AUTHOR=Ibrahim Vanessa , Isroff Catherine , Stephen Christopher D. , Iyer Jay , Dale Marian L. , Gunzler Douglas A. , Bayram Ece , Xie Tao , Pantelyat Alex , Montaser-Kouhsari Leila , Garcia-Cordero Indira , Tartaglia Maria Carmela , Lang Anthony E. , Swan Matthew , Boxer Adam L. , Golbe Lawrence I. , Wills Anne-Marie 

TITLE=Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy

JOURNAL=Frontiers in Neurology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1501206

DOI=10.3389/fneur.2024.1501206

ISSN=1664-2295

ABSTRACT=BackgroundThe Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.ObjectivesTo evaluate the MoCA as an outcome measure in PSP clinical trials.MethodsCognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation.ResultsThere was a significant decline in the MoCA score over time of −1.4 (95% CI −0.84 to −1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (rrm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (rrm = −0.25, p < 0.0001).ConclusionThe MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.